Logo

Intellia Therapeutics, Inc.

NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and al… read more

Healthcare

Biotechnology

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$10.77

Price

+0.84%

$0.09

Market Cap

$1.209b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-624.9%

EBITDA Margin

-639.5%

Net Profit Margin

-780.3%

Free Cash Flow Margin

-624.9%

EBITDA Margin

-639.5%

Net Profit Margin

-780.3%

Free Cash Flow Margin
Revenue

$66.092m

-2.3%

1y CAGR

+24.7%

3y CAGR

+10.9%

5y CAGR
Earnings

-$394.596m

+4.4%

1y CAGR

+5.7%

3y CAGR

+3.9%

5y CAGR
EPS

-$3.54

+7.1%

1y CAGR

+12.6%

3y CAGR

+12.4%

5y CAGR
Book Value

$620.939m

$758.779m

Assets

$137.840m

Liabilities

$80.490m

Debt
Debt to Assets

10.6%

-0.2x

Debt to EBITDA
Free Cash Flow

-$363.625m

-2.5%

1y CAGR

+3.5%

3y CAGR

+1.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases